Elekta's Evo CT-Linac Wins FDA Approval, Reshaping Precision Radiation Therapy

Elekta has announced a significant breakthrough in cancer treatment technology: its Evo CT-Linac system has received FDA 510(k) clearance, making it available to radiation oncology centers across the United States. This approval represents a major milestone for the Swedish medical device company, as the advanced linac technology is now positioned to transform how clinicians deliver personalized radiation therapy to cancer patients nationwide.

The Evo linac distinguishes itself by integrating high-quality CT imaging directly into the radiation delivery platform, enabling clinicians to visualize tumors and critical organs with unprecedented clarity during each treatment session. This real-time imaging capability allows healthcare professionals to make immediate treatment adjustments, potentially improving clinical outcomes while maintaining the speed and efficiency that modern cancer centers require.

Advanced Imaging Meets Precision Treatment: Inside the Evo Linac Technology

At the core of the Evo linac system lies Iris, a revolutionary imaging innovation that addresses one of radiation oncology’s most persistent technical challenges. Iris leverages AI-powered algorithms to minimize image scatter—a common problem in traditional cone-beam CT systems that can compromise image quality. By dramatically reducing scatter through advanced processing techniques, the linac’s imaging system delivers sharper, clearer visualization of soft tissue structures and anatomical landmarks.

This enhanced image quality has direct clinical implications. Clinicians can identify tumor boundaries with greater precision and pinpoint sensitive structures that must be protected during treatment. The result is more accurate patient positioning before each therapy session and the ability to adapt treatment plans confidently as anatomical changes occur throughout the course of therapy. Clinical validation from leading institutions like the Medical College of Wisconsin, which partnered in Iris development, confirms the system’s ability to deliver substantially improved image clarity compared to conventional cone-beam approaches.

Beyond imaging performance, the Evo linac offers a practical advantage: Iris can be deployed as an upgrade to existing linear accelerators. This flexibility lowers adoption barriers for clinics and extends the useful lifespan of installed equipment, making advanced technology accessible across healthcare facilities of varying sizes and ages.

Competitive Positioning and Market Opportunities

The FDA clearance strengthens Elekta’s competitive stance in the U.S. radiation oncology market. By combining advanced imaging, AI-driven analysis, and operational flexibility within a single linac platform, Elekta offers clinics an integrated solution that competitors have not yet fully matched. The company’s strategy emphasizes modernization of cancer treatment capabilities, enabling providers to adopt advanced diagnostics and raise clinical care standards across the United States.

For revenue growth, FDA approval opens significant commercialization opportunities. Increased adoption of the Evo linac in clinical settings can drive incremental sales while deepening customer relationships. Additionally, the system’s upgrade pathway and service requirements support recurring revenue streams—a crucial element in medical device company financial sustainability.

Elekta’s market capitalization currently stands at $2.51 billion, reflecting investor confidence in the company’s innovation trajectory and market prospects. Since the FDA announcement, Elekta’s stock (EKTAY) has gained 3.7%, with six-month performance reaching 38.4%—substantially outpacing the medical device industry’s 12.2% gain and the S&P 500’s 12.8% increase during the same period.

Radiation Therapy Market Expands Amid Growing Demand

Industry analysis reveals robust tailwinds supporting the linac market. According to Precedence Research, the global radiation therapy market was valued at approximately $8.6 billion in 2026 and is projected to expand at a compound annual growth rate (CAGR) of 9% through 2035. Primary growth drivers include rising cancer incidence globally, increased demand for precision treatment technologies, and growing adoption of AI-enhanced diagnostic and therapeutic tools.

This expanding market creates substantial opportunity for innovative linac solutions. As healthcare systems prioritize personalized medicine and improved patient outcomes, demand for integrated imaging-and-therapy platforms like the Evo linac should intensify. Elekta’s early FDA clearance positions the company favorably to capture market share during this growth phase.

Strategic Transformation Enhancing Operational Efficiency

Beyond product innovation, Elekta is undergoing organizational transformation designed to accelerate product development, strengthen commercial execution, and improve operational efficiency. The company is decentralizing decision-making authority to enable faster market responsiveness. This restructuring is expected to generate annual cost savings of at least SEK 500 million, with full financial impact materializing in Q1 of fiscal 2026.

Simultaneously, Elekta completed a comprehensive review of its order backlog, applying stricter criteria for order recognition. This process resulted in cancellation of SEK 2,197 million in orders, a necessary step to improve revenue predictability and support long-term profitability. While this action temporarily reduced the reported order book, it reflects management’s commitment to sustainable, quality-focused growth rather than pursuing low-margin or uncertain deals.

These strategic initiatives—product innovation through advanced linac systems, operational restructuring, and financial discipline—collectively position Elekta for sustained competitive advantage in radiation oncology. The Evo linac’s FDA approval exemplifies how the company is translating research and development investments into commercially impactful solutions that improve clinical care while generating shareholder value in an expanding therapeutic market.